Definitive Contract N6600123C4509
Award Date
5/2/23
Potential Completion Date
5/21/25
Potential Value
$4M
Federal Agency
Naval Information Warfare Systems Command
Awardee
Ginkgo Bioworks, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
AJ12 - General Science And Technology R&D Services; General Science And Technology; Applied Research
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Boston, MA 02210, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
22
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Cost Plus Fixed Fee contract awarded by the Navy NAVSUP Engineering Logistics Office to Ginkgo Bioworks, Inc., a Boston-based biotechnology company, for the IARPA FELIX PROGRAM. The contract has a ceiling value of $5,338,550.00 and a completion date of June 30, 2022. Ginkgo Bioworks is a for-profit manufacturer of goods that specializes in cellular engineering, DNA sequencing, and advanced biological manufacturing services. The company has a proven track record of delivering complex...
This federal contract award from the Defense Advanced Research Projects Agency (DARPA) to Ginkgo Bioworks, Inc., a Boston-based biotechnology company, has a total ceiling value of $10,446,304.00. The purpose of this Cost Plus Fixed Fee contract is to have Ginkgo Bioworks serve as a TA3 SD2 performer, developing software interfaces to transition generated synthetic biological test results to other software systems as part of the GINKGO BIOWORKS SD2 PROGRAM. This contract is not set aside for...
This is a $4,797,261 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Ginkgo Bioworks, Inc., a biotechnology company based in Boston. The contract is for DARPA's "SUPERB: SYNBIO + UNIVERSAL PURIFICATION OF EXTRACT-DERIVED, RIGHT-ON-TIME BIOLOGICS" program, which aims to develop technologies enabling immediate synthesis of bioactive protein medical countermeasures and production enzymes within 24 hours at a yield of at least 500 doses per week....
This $50,216,772.13 Firm Fixed Price Delivery Order contract was awarded to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract is for test surge and data sharing services under a larger Indefinite Delivery/Indefinite Quantity (IDIQ) vehicle held with the Centers for Disease Control and Prevention (CDC). The IDIQ has a total ceiling value of $118 million and an ultimate completion date of September 5, 2029. Ginkgo Bioworks has previously provided...
This is a $1,205,149.24 Firm Fixed Price contract awarded by the Centers for Disease Control and Prevention (CDC) to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract, titled "TRAVELER-BASED GENOMIC SURVEILLANCE," is for the provision of biotechnology services to support the CDC's public health monitoring and emergency response initiatives. The contract has an ultimate completion date of September 19, 2024 and was awarded on August 26, 2024....
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $85,741,227.24 Firm Fixed Price Definitive Contract to Ginkgo Bioworks, Inc., a biotechnology company in Boston, Massachusetts, for a Traveler-Based Genomic Surveillance Program. The contract has an ultimate completion date of March 21, 2028 and was not set aside for a specific business category. This contract appears to build on Ginkgo Bioworks' previous work with the CDC on COVID-19 genomic testing and surveillance at major...
This federal contract award is for a delivery order under the "Test Surge and Data Sharing Multiple Award IDIQ" issued by the Centers for Disease Control and Prevention (CDC). The prime contractor is Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract has a ceiling value of $449,761.53 and a completion date of May 15, 2025. It is a time and materials contract type, with no set-aside designation. The contract leverages Ginkgo Bioworks' expertise...
This is a federal contract award from the Defense Advanced Research Projects Agency (DARPA) to Ginkgo Bioworks, Inc., a Boston-based biotechnology company. The contract, valued at $11,229,364.00, is for the "Ice Control for Cold Environments (ICE)" program, which seeks to develop solutions for extreme cold weather operational challenges faced by the Department of Defense (DoD). The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, and the ultimate completion...
This is a $14,605,403.00 cost-plus-fixed-fee definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Ginkgo Bioworks, Inc., a Boston-based biotechnology company. The contract is part of DARPA's ReVector program, which aims to develop methods to use human skin microbiomes to modulate chemical production in order to avoid mosquito attraction and feeding, thereby reducing the threat of mosquito-borne disease to U.S. military personnel. The original solicitation, with...
The Centers for Disease Control and Prevention (CDC) awarded a $76,575,638.04 firm-fixed-price contract to Ginkgo Bioworks, Inc., a Boston-based biotechnology company, to conduct genomic testing and surveillance of SARS-CoV-2 at five major U.S. international airports. The contract, which runs through March 21, 2025, requires Ginkgo Bioworks to collect a minimum of 483,000 biological samples per year from international travelers and perform on-site reverse transcription polymerase chain...